Design to come?
WP_Post Object ( [ID] => 511 [post_author] => 3 [post_date] => 2020-09-17 14:09:58 [post_date_gmt] => 2020-09-17 19:09:58 [post_content] => [post_title] => Intensity Therapeutics Doses First Patient with Combination of INT230-6 and Bristol Myers Squibb’s Yervoy® in a Phase 2 Study [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => intensity-therapeutics [to_ping] => [pinged] => [post_modified] => 2020-10-07 14:12:56 [post_modified_gmt] => 2020-10-07 19:12:56 [post_content_filtered] => [post_parent] => 0 [guid] => http://vcapital.localhost/?post_type=news&p=511 [menu_order] => 0 [post_type] => news [post_mime_type] => [comment_count] => 0 [filter] => raw )